Cure8 trial brief
Head-to-head comparisons between biologics are uncommon but useful for patients and clinicians deciding between agents. This study specifically compares ustekinumab and infliximab for remission, safety, and quality of life in ulcerative colitis.
Patients with ulcerative colitis considering biologic therapy; clinicians prescribing biologics; researchers in IBD therapeutics.
This ClinicalTrials.gov record describes an observational head-to-head study comparing ustekinumab versus infliximab in people with ulcerative colitis. The study aims to compare effectiveness for achieving remission, safety, and quality-of-life outcomes, and plans to enroll about 100 participants.
The trial record lists the specific interventions and dosing approach for each drug (weight-based IV induction and subcutaneous maintenance for ustekinumab; standard infliximab dosing). It frames the study as addressing a knowledge gap because randomized head-to-head data are limited, particularly in the Egyptian population referenced by the investigators.
The registry status is Active, Not Recruiting, and the record is labeled as an observational study rather than a randomized controlled trial. That affects how results should be interpreted: observational comparisons can show associations but are more susceptible to bias than randomized trials.
This is a ClinicalTrials.gov registry entry (trial-record) describing planned observational comparisons; it does not present study results. The observational design means findings will be subject to confounding compared with randomized trials.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study models comparative cost-effectiveness across many advanced therapy sequences for moderate–severe ulcerative colitis in Japan; its findings could influence how health systems and clinicians consider first- and...
Early changes in stool tests (qFIT and fecal calprotectin) might help predict which biologic‑naive ulcerative colitis patients will relapse or need escalation to biologic/JAK therapy. If validated, such markers could...
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
